Search results
Results from the WOW.Com Content Network
The dendritic cell-based cancer vaccine is an innovation in therapeutic strategy for cancer patients. Dendritic cells (DCs) are antigen presenting cells for the induction of antigen specific T cell response. [1] DC-based immunotherapy is safe and can promote antitumor immune responses and prolonged survival of cancer patients. [2]
Dendritic cell therapy provokes anti-tumor responses by causing dendritic cells to present tumor antigens to lymphocytes, which activates them, priming them to kill other cells that present the antigen. Dendritic cells are antigen-presenting cells (APCs) in the mammalian immune system. [14] In cancer treatment, they aid cancer antigen targeting ...
Vaccine therapy is a type of treatment that uses a substance or group of ... Dendritic cells (DCs) are considered the most potent APC (antigen presenting cell) of the ...
A major application of cellular adoptive therapy is cancer treatment, as the immune system plays a vital role in the development and growth of cancer. [1] The primary types of cellular adoptive immunotherapies are T cell therapies. Other therapies include CAR-T therapy, CAR-NK therapy, macrophage-based immunotherapy and dendritic cell therapy.
A dendritic cell (DC) is an antigen-presenting cell (also known as an accessory cell) of the mammalian immune system.A DC's main function is to process antigen material and present it on the cell surface to the T cells of the immune system.
Dendreon Pharmaceuticals LLC is a biotechnology company. Its lead product, Provenge (known generically as sipuleucel-T), is an immunotherapy for prostate cancer.It consists of a mixture of the patient's own blood cells (autologous, with dendritic cells thought to be the most important) that have been incubated with the Dendreon PAP-GM-CSF fusion protein.
A course of treatment consists of three basic steps: The patient's white blood cells, primarily dendritic cells, a type of antigen-presenting cells (APCs), are extracted in a leukapheresis procedure. The blood product is sent to a production facility and incubated with a fusion protein (PA2024) consisting of two parts:
They include T cells and B cells and are part of the larger category of ‘tumor-infiltrating immune cells’ which consist of both mononuclear and polymorphonuclear immune cells, (i.e., T cells, B cells, natural killer cells, macrophages, neutrophils, dendritic cells, mast cells, eosinophils, basophils, etc.) in variable proportions. Their ...